Solin

Researchers are studying the safety and effectiveness of NNC0487-0111 for adults with excess body weight and type 2 diabetes. This Phase 3 clinical trial compares NNC0487-0111 with a placebo to see how well the medicine helps reduce body weight when taken along with diet and exercise changes. Participants have type 2 diabetes for at least six months and meet specific health criteria to join the study. Participants are randomly assigned to receive one of four different doses of NNC0487-0111 or a placebo. Each treatment is given as a weekly injection under the skin using a pre-filled pen injector, targeting areas like the thigh, abdomen, or upper arm. All participants follow a reduced-calorie diet and increase physical activity during the study. The main treatment period lasts 84 weeks, with body weight and other health measures tracked throughout. During the study, participants will have regular assessments including blood tests to check blood sugar levels, cholesterol, and other health markers. Researchers will also monitor waist size, blood pressure, and quality of life related to physical function. Safety is carefully watched by tracking any side effects or adverse events until 88 weeks. Overall, participants are involved in frequent visits and health evaluations to measure treatment impact and safety over nearly two years.